Scarica l'app Stockscreener
17.48
1.19%
-0.21
Dopo l'orario di chiusura:
17.48
Kailera Therapeutics Inc Borsa (KLRA) Ultime notizie
Kailera Therapeutics (KLRA) Stock Price, News & Analysis $KLRA - MarketBeat
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
Patent fight erupts around next generation of multibillion-dollar GLP-1 weight-loss drugs - The Business Journals
Yuting Liu Net Worth (2026) - GuruFocus
Jamie Beth Coleman Net Worth (2026) - GuruFocus
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Net Worth (2026) - GuruFocus
Parabilis tops Kailera as biopharma IPOs surge to best H1 since 2021 - BioWorld News
Scott M. Wasserman Net Worth (2026) - GuruFocus
Stuart Partners, Llc Net Worth (2026) - GuruFocus
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Short Interest Up 96.0% in June - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Hits New 52-Week LowWhat's Next? - MarketBeat
KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart - MEXC
Kailera Therapeutics (KLRA) is One of the Best IPO Stocks with Huge Upside Potential - Yahoo Finance
Kailera's obesity drug meets main goal of late-stage trials in China - MSN
Kailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To Win - Seeking Alpha
5 Best IPO Stocks with Huge Upside Potential - Insider Monkey
Kailera Therapeutics (KLRA) officer receives 175,000 stock options at $23.30 strike - Stock Titan
Kailera Therapeutics (KLRA) officer Kathleen Tregoning files initial Form 3 - Stock Titan
Jefferies Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Kailera weight loss pill trial results: Nausea sinks stock - qz.com
Europe will accelerate its review of RevMed’s drug - STAT
Kailera reports positive Phase III data for oral GLP-1 obesity candidate - The Pharma Letter
Kailera shares tumble on high nausea rates despite weight-loss drug's success | Business Information & News | FE - Westlaw Today
Kailera Therapeutics (KLRA) Company presentation Summary - Quartr
Kailera Therapeutics (KLRA) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Kailera Therapeutics (KLRA) Registration filing Summary - Quartr
Kailera falls after late-stage trial data for oral GLP-1 candidate - MSN
Kailera/Hengrui’s Oral GLP-1 Looks Effective, But GI Toxicity Raises Concern - insights.citeline.com
Kailera shares tumble on high nausea rates despite weight-loss drug's success - MSN
Update: Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial; Shares Fall - Moomoo
Kailera shares tumble on high nausea rates despite weight-loss drug’s success - Y100 WNCY
The stock price of Kailera Therapeutics, Inc. (KLRA) rose by 1.9% in pre-market trading. - Bitget
TD Cowen Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Announces Target Price $57 - Moomoo
Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback - Investor's Business Daily
Kailera reports 11.1% weight loss data - grafa.com
Kailera says obesity pill succeeds in late-stage trial in China - BioPharma Dive
Kailera posts late-stage trial data for oral GLP-1 drug (KLRA) - Seeking Alpha
Kailera Therapeutics Announces Positive Topline Data From Two Hengrui Pharma Phase 3 Clinical Trials Of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535 - marketscreener.com
Kailera’s obesity drug meets main goal of late-stage trials in China - 101 WIXX
Kailera’s weight-loss drug meets main goal of late-stage trials in China - hi99.com
Kailera's weight-loss drug meets main goal of late-stage trials in China - marketscreener.com
Kailera's GLP-1 drug meets main goal of late-stage trials - Yahoo Finance
Kailera Therapeutics Announces Positive Topline Data from - GlobeNewswire
Kailera Therapeutics (KLRA) Stock Looks Overvalued Despite Its 20% Slump - Yahoo Finance
Kailera appoints Kathleen Tregoning as chief corporate affairs officer - The Pharma Letter
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Index - marketscreener.com
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Value Benchmark - marketscreener.com
Kailera Appoints New Chief Corporate Affairs Officer - Intellectia AI
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer - The Manila Times
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Growth Benchmark - marketscreener.com
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):